Reactive cutaneous capillary endothelial proliferations of the eyelids induced by camrelizumab: A case report

• DOI: 10.3892/br.2024.1743
• Publication Date: 2024-02-01T07:10:23Z
• Authors: Xuecong Zhou; Xiaoming Yan; Yuan Wu

With the widespread application of immune checkpoint inhibitors, a series adverse events (AEs) related to treatment resulting from alterations in system have emerged that warrant attention. The present study report case patient with reactive cutaneous capillary endothelial proliferations (RCCEPs) on eye lid, following programmed cell death protein 1 inhibitor camrelizumab (SHR‑1210) for stage IIa2 well‑ moderately differentiated squamous carcinoma cervix. Although RCCEPs been revealed be most common AEs SHR‑1210, they are usually distributed head, neck, trunk and extremities. current presents rare ocular induced by SHR‑1210. Prompt diagnosis immune‑related is crucial optimal management patients. slight‑risk toxicities pose no threat continuity treatment, lesions unusual distributions cause disturbances normal life require proper such as surgical excision.